



July 1, 2021

Dear Joslyn and Justin,

As you know, Mallinckrodt Pharmaceuticals has reached an agreement to divest and transfer the Investigational New Drug (IND) application for the experimental drug adrabetadex (VTS-270) to MANDOS, LLC (“Mandos”). This transaction has now closed following approval by the U.S. Bankruptcy Court for the District of Delaware as part of Mallinckrodt’s Chapter 11 filing.

We recognize that this transition may raise some questions for you, your organization, and the patients and caregivers in the NPC community. We want to assure you that we are continuing to work with Mandos to complete the previously communicated wind down and closure of Mallinckrodt’s existing clinical program over the course of the next several months. During this time, Mallinckrodt will continue to oversee the clinical trials through study completion.

Additionally, as part of this transaction, Mandos and Mallinckrodt have worked to secure drug supply to allow continued support for the existing North American Expanded Access Programs. We will support the efforts to ensure a smooth transition of these programs. In addition, we expect Mandos to reach out to you shortly with details about its plans for both expanded access and future research and development of adrabetadex. If you have any immediate questions or concerns, please contact Scott Riccio, EVP, Patient & Community Engagement.

Once again, we would like to thank you for your support over the past several years. It has been a privilege to work with so many passionate and dedicated individuals and organizations in the NPC advocacy community. We are also deeply grateful to the patients, families, and treating physicians who have participated in and supported our clinical development program. With your continued collaboration, we are hopeful that Mandos will be able to advance further both the understanding of the disease, and the potential to develop adrabetadex as a future treatment option for NPC patients.

Sincerely,

Sheila

Sheila Talafous
Director, Advocacy Relations
Mallinckrodt Pharmaceuticals